Lowering the positivity threshold of a commercial fecal immunochemical test (FIT) can enhance its sensitivity to levels comparable to next-generation multitarget stool DNA tests (NG-MSDT) while maintaining comparable specificity. This makes FIT a cost-effective and accessible noninvasive screening option for colorectal cancer (CRC), especially for patients who cannot undergo colonoscopies or are at lower CRC risk.
A study analyzing data from the BLITZ and BLUE-C cohorts found that adjusting FIT thresholds improved sensitivity for CRC detection without significantly compromising specificity, suggesting it as a viable alternative to NG-MSDT for early CRC diagnosis and improved patient outcomes.
Keep Reading
Add A Comment